REFRACTORY CANCER

This early-stage study tests a new drug, ADU-1805, in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with another cancer drug (pembrolizumab). The main goals are to check safety and how the body processes the drug. Abo…

This study tests a new drug combination (epcoritamab plus chemotherapy) in 32 adults whose large B-cell lymphoma has returned or not responded to prior treatment. The goal is to see if this approach can shrink tumors and help patients become eligible for a stem cell transplant or…

This study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like lymphoma) that have returned or not responded to prior therapy. The study will enroll about 80 …

This study looks at whether a cancer drug called teclistamab can be given safely in an outpatient clinic instead of the hospital for people with relapsed or refractory multiple myeloma. It involves 15 adults who have already tried at least three other treatments. The goal is to c…

This study tests a combination of two drugs (zanubrutinib and pemetrexed) followed by zanubrutinib alone for people with a type of brain lymphoma that has returned or not responded to prior treatment. The goal is to see how well the treatment shrinks tumors and controls the disea…

This study tests whether adding omeprazole (a common heartburn medicine) to standard chemotherapy can help shrink tumors or slow cancer growth in men with advanced prostate cancer that has stopped responding to other treatments. About 50 men will receive either cabazitaxel or doc…

This study is testing an experimental radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The drug is designed to deliver radiation directly to tumors. The main goals ar…

This study tests new cancer drugs that are chosen based on the unique genetic makeup of each child's tumor. It is for children, teens, and young adults with advanced solid tumors, brain tumors, or lymphoma that have not responded to standard treatments. The goal is to find the ri…

This early-stage study is testing a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with solid tumors that have returned or not responded to treatment. The main goal is to find a safe dose and check for side effects. The study is…

This study is for people with head and neck cancer that has returned after standard treatments. It tests a new therapy where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. The main goals are to see if the treatment is safe and to f…

This early-phase trial tests an experimental drug called IMA402 in about 145 adults with advanced solid tumors that have returned or not responded to standard treatments. IMA402 is a bispecific T-cell engager designed to direct the immune system to attack cancer cells carrying a …

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. Some participants will also receive an immunotherapy drug …

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can control the cancer for at least 6 months. About 3…